{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T01:08:36Z","timestamp":1774314516551,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,9]]},"DOI":"10.7759\/cureus.101174","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T16:42:01Z","timestamp":1767976921000},"source":"Crossref","is-referenced-by-count":1,"title":["Unmasking Hemophagocytic Lymphohistiocytosis After Minimal Tumor Necrosis Factor-Alpha (TNF-\u03b1) Blockade: An Interplay of Contributing Elements"],"prefix":"10.7759","author":[{"given":"Shaivya","family":"Pathak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000239","article-title":"Paradoxical reactions under TNF-\u03b1 blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview","volume":"2","author":"Toussirot \u00c9","year":"2016","unstructured":"Toussirot \u00c9, Aubin F. Paradoxical reactions under TNF-\u03b1 blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open. 2016, 2:e000239. 10.1136\/rmdopen-2015-000239","journal-title":"RMD Open"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez379","article-title":"Haemophagocytic lymphohisticytosis-an underrecognized hyperinflammatory syndrome","volume":"58","author":"Hutchinson M","year":"2019","unstructured":"Hutchinson M, Tattersall RS, Manson JJ. Haemophagocytic lymphohisticytosis-an underrecognized hyperinflammatory syndrome. Rheumatology (Oxford). 2019, 58:vi23-30. 10.1093\/rheumatology\/kez379","journal-title":"Rheumatology (Oxford)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2015.07.004","article-title":"Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies","volume":"45","author":"Brito-Zer\u00f3n P","year":"2016","unstructured":"Brito-Zer\u00f3n P, Bosch X, P\u00e9rez-de-Lis M, et al.. Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies. Semin Arthritis Rheum. 2016, 45:391-9. 10.1016\/j.semarthrit.2015.07.004","journal-title":"Semin Arthritis Rheum"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4387-5","article-title":"Macrophage activation syndrome in a patient with axial spondyloarthritis on adalimumab","volume":"38","author":"Baker R","year":"2019","unstructured":"Baker R, Liew JW, Simonson PD, Soma LA, Starkebaum G. Macrophage activation syndrome in a patient with axial spondyloarthritis on adalimumab. Clin Rheumatol. 2019, 38:603-8. 10.1007\/s10067-018-4387-5","journal-title":"Clin Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s42358-024-00370-2","article-title":"Hemophagocytic lymphohistiocytosis and macrophage activation syndrome: two rare sides of the same devastating coin","volume":"64","author":"Sztajnbok F","year":"2024","unstructured":"Sztajnbok F, Fonseca AR, Campos LR, et al.. Hemophagocytic lymphohistiocytosis and macrophage activation syndrome: two rare sides of the same devastating coin. Adv Rheumatol. 2024, 64:28. 10.1186\/s42358-024-00370-2","journal-title":"Adv Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2011.09.004","article-title":"Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1","volume":"22","author":"Van Hauwermeiren F","year":"2011","unstructured":"Van Hauwermeiren F, Vandenbroucke RE, Libert C. Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1. Cytokine Growth Factor Rev. 2011, 22:311-9. 10.1016\/j.cytogfr.2011.09.004","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref7","doi-asserted-by":"crossref","DOI":"10.1172\/JCI36389","article-title":"Evidence that cytokines play a role in rheumatoid arthritis","volume":"118","author":"Brennan FM","year":"2008","unstructured":"Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest. 2008, 118:3537-45.","journal-title":"J Clin Invest"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20140964","article-title":"Failed CTL\/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time","volume":"212","author":"Jenkins MR","year":"2015","unstructured":"Jenkins MR, Rudd-Schmidt JA, Lopez JA, et al.. Failed CTL\/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time. J Exp Med. 2015, 212:307-17. 10.1084\/jem.20140964","journal-title":"J Exp Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/nri3834","article-title":"Regulation of tumour necrosis factor signalling: live or let die","volume":"15","author":"Brenner D","year":"2015","unstructured":"Brenner D, Blaser H, Mak TW. Regulation of tumour necrosis factor signalling: live or let die. Nat Rev Immunol. 2015, 15:362-74. 10.1038\/nri3834","journal-title":"Nat Rev Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2015.1058159","article-title":"Clinical features and correct diagnosis of macrophage activation syndrome","volume":"11","author":"Cron RQ","year":"2015","unstructured":"Cron RQ, Davi S, Minoia F, Ravelli A. Clinical features and correct diagnosis of macrophage activation syndrome. Expert Rev Clin Immunol. 2015, 11:1043-53. 10.1586\/1744666X.2015.1058159","journal-title":"Expert Rev Clin Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-788349","article-title":"Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study","volume":"130","author":"Bergsten E","year":"2017","unstructured":"Bergsten E, Horne A, Aric\u00f3 M, et al.. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017, 130:2728-38. 10.1182\/blood-2017-06-788349","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018894618","article-title":"Recommendations for the management of hemophagocytic lymphohistiocytosis in adults","volume":"133","author":"La Ros\u00e9e P","year":"2019","unstructured":"La Ros\u00e9e P, Horne A, Hines M, et al.. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019, 133:2465-77. 10.1182\/blood.2018894618","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2012.3","article-title":"Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment","volume":"13","author":"Ravelli A","year":"2012","unstructured":"Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun. 2012, 13:289-98. 10.1038\/gene.2012.3","journal-title":"Genes Immun"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27929","article-title":"Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: recommendations from the North American Consortium for Histiocytosis (NACHO)","volume":"66","author":"Jordan MB","year":"2019","unstructured":"Jordan MB, Allen CE, Greenberg J, et al.. Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: recommendations from the North American Consortium for Histiocytosis (NACHO). Pediatr Blood Cancer. 2019, 66:e27929. 10.1002\/pbc.27929","journal-title":"Pediatr Blood Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti F","year":"2012","unstructured":"De Benedetti F, Brunner HI, Ruperto N, et al.. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012, 367:2385-95. 10.1056\/NEJMoa1112802","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.04.010","article-title":"Abatacept for Crohn's disease and ulcerative colitis","volume":"143","author":"Sandborn WJ","year":"2012","unstructured":"Sandborn WJ, Colombel JF, Sands BE, et al.. Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology. 2012, 143:62-69.e4. 10.1053\/j.gastro.2012.04.010","journal-title":"Gastroenterology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen SB","year":"2006","unstructured":"Cohen SB, Emery P, Greenwald MW, et al.. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006, 54:2793-806. 10.1002\/art.22025","journal-title":"Arthritis Rheum"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/art.38802","article-title":"Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients","volume":"66","author":"Minoia F","year":"2014","unstructured":"Minoia F, Dav\u00ec S, Horne A, et al.. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol. 2014, 66:3160-9. 10.1002\/art.38802","journal-title":"Arthritis Rheumatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/445722-unmasking-hemophagocytic-lymphohistiocytosis-after-minimal-tumor-necrosis-factor-alpha-tnf--blockade-an-interplay-of-contributing-elements","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T16:42:02Z","timestamp":1767976922000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/445722-unmasking-hemophagocytic-lymphohistiocytosis-after-minimal-tumor-necrosis-factor-alpha-tnf--blockade-an-interplay-of-contributing-elements"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.101174","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,9]]}}}